Treatable traits: a comprehensive precision medicine approach in interstitial lung disease
European Respiratory Journal · 2023-07 · 62 (1) · 2300404
DOI: 10.1183/13993003.00404-2023 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 01.06.2023. Verfasst von Yet H Khor und 9 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Research@Alfred, Central Clinical School, Monash University, Melbourne, Australia yet.khor@monash.edu. Hauptthemen laut MEDLINE: Precision Medicine, Lung Diseases, Interstitial. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Health and Medical Research Council.
Abstract (Originalsprache)
Interstitial lung disease (ILD) is a diverse group of inflammatory and fibrotic lung conditions causing significant morbidity and mortality. A multitude of factors beyond the lungs influence symptoms, health-related quality of life, disease progression and survival in patients with ILD. Despite an increasing emphasis on multidisciplinary management in ILD, the absence of a framework for assessment and delivery of comprehensive patient care poses challenges in clinical practice. The treatable traits approach is a precision medicine care model that operates on the premise of individualised multidimensional assessment for distinct traits that can be targeted by specific interventions. The potential utility of this approach has been described in airway diseases, but has not been adequately considered in ILD. Given the similar disease heterogeneity and complexity between ILD and airway diseases, we explore the concept and potential application of the treatable traits approach in ILD. A framework of aetiological, pulmonary, extrapulmonary and behavioural and lifestyle treatable traits relevant to clinical care and outcomes for patients with ILD is proposed. We further describe key research directions to evaluate the application of the treatable traits approach towards advancing patient care and health outcomes in ILD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Respiratory Research@Alfred, Central Clinical School, Monash University, Melbourne, Australia yet.khor@monash.edu.
- Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Australia.
- Institute for Breathing and Sleep, Heidelberg, Australia.
- Faculty of Medicine, University of Melbourne, Melbourne, Australia.
- National Coordinating Reference Centre for Rare Pulmonary Diseases, OrphaLung, Louis Pradel Hospital, Hospices Civils de Lyon, ERN-LUNG, Lyon, France.
- UMR 754, Claude Bernard University Lyon 1, INRAE, Lyon, France.
ORCID-Profile: Yet H Khor, Vincent Cottin, Anne E Holland, Yoshikazu Inoue, Anne Marie Russell
Förderung
- NHLBI NIH HHS
- National Health and Medical Research Council
Zitieren
APA
Khor, Y. H., Cottin, V., Holland, A. E., Inoue, Y., McDonald, V. M., Oldham, J., Renzoni, E. A., Russell, A. M., Strek, M. E., & Ryerson, C. J. (2023). Treatable traits: a comprehensive precision medicine approach in interstitial lung disease. European Respiratory Journal, 62(1), 2300404. https://doi.org/10.1183/13993003.00404-2023
Vancouver
Khor YH, Cottin V, Holland AE, Inoue Y, McDonald VM, Oldham J, et al. Treatable traits: a comprehensive precision medicine approach in interstitial lung disease. European Respiratory Journal. 2023;62(1):2300404. doi:10.1183/13993003.00404-2023
BibTeX
@article{Khor2023,
author = {Khor, Yet H and Cottin, Vincent and Holland, Anne E and Inoue, Yoshikazu and McDonald, Vanessa M and Oldham, Justin and Renzoni, Elisabetta A and Russell, Anne Marie and Strek, Mary E and Ryerson, Christopher J},
title = {Treatable traits: a comprehensive precision medicine approach in interstitial lung disease},
journal = {European Respiratory Journal},
year = {2023},
volume = {62},
number = {1},
pages = {2300404},
doi = {10.1183/13993003.00404-2023}
}
EUVIMED